Correction: Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis,BMJ Neurology Open

当前位置： X-MOL 学术 › BMJ Neurol. Open › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Correction: Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis
BMJ Neurology Open Pub Date : 2021-07-01 , DOI: 10.1136/bmjno-2020-000096corr1
BMJ Publishing Group Ltd

Karunaratne K, Ahrabian D, Monoghan B, et al . Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis. BMJ Neurol Open 2021;3:e000096. doi:10.1136/bmjno-2020-000096 The article has been corrected since it was first published. The published version

中文翻译：

更正：硼替佐米用于治疗多发性硬化症患者达利珠单抗治疗后的抗 NMDAR 脑炎

Karunaratne K、Ahrabian D、Monoghan B 等。硼替佐米用于多发性硬化症患者达利珠单抗治疗后的抗 NMDAR 脑炎。2021 年 BMJ 神经公开赛；3：e000096。doi:10.1136/bmjno-2020-000096 文章自首次发表后已更正。已发布版本

更新日期：2021-07-24

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文

全部期刊列表>>